Pierre Fabre and Cordeliers Research Center join forces

14 December 2015

French pharmaceutical company Pierre Fabre’s Center of Immunology (CIPF) has entered into a three-year collaboration with the Corderliers Research Centre (CRC) to develop oncology biotherapies, it has been announced.

The partnership, which will bring together CRC’s academic scientific excellence and Pierre Fabre’s know-how in developing biomolecules, aims to bridge the gap between academic and applied research.

Professor Wolf-Hervé Fridman, who founded CRC, said: “Most of my research has been dedicated to fighting cancer and discovering the best approach to win this fight. By combining our respective expertise, this partnership offers us a unique opportunity to promote the development of our latest discoveries so that they can become innovative anti-cancer immunotherapies.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK